Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →. With Zai Lab (China only).
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
547actual
Sites
300
Countries
Argentina, Australia, Belgium +34
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-07 | actual | When the study began enrolling |
| Primary completion | 2025-06-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-26 | actual | The whole study's end, after follow-up |
| First posted | 2021-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
- Drug: Bemarituzumab
- Drug: mFOLFOX6
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Up to approximately 3.5 years
Publications
- PMID 39854659 — cited as background
- PMID 40355729 — cited as background
- PMID 40341124 — linked by the registry
- PMID 38308771 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed